Compare DexCom, Inc. (DXCM) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Plby Group Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Plby Group Inc trades at $1.33 (market cap $162.94M). The key difference: DexCom, Inc. is far larger — about 207.4× Plby Group Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | PLBY | |
|---|---|---|
Market Cap | $33.79B | $162.94M |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $2.71 |
52-Week Low | $54.84 | $1.11 |
Enterprise Value | $33.24B | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
PLBY Group trades at $1.255, up 6.36% with bullish technical signals from moving averages. The company shows improving fundamentals with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains thin at 0.23%. Recent developments include inclusion in Russell indexes and strategic share repurchases. Analyst consensus is strongly positive with 75% buy ratings.
The outlook suggests gradual recovery with projected 2026 profitability, though high P/E of 68 and negative shareholder equity pose valuation concerns. Key opportunities include licensing growth and brand expansion, while risks involve debt burden and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
